Receptor for advanced glycation end products is a promising target of diabetic nephropathy

Ann N Y Acad Sci. 2005 Jun;1043:562-6. doi: 10.1196/annals.1333.064.

Abstract

Advanced glycation end products (AGEs) and the receptor for AGE (RAGE) interactions have been implicated in the development of diabetic vascular complications, which cause various disabilities and shortened life expectancy, and reduced quality of life in patients with diabetes. Diabetes-induced RAGE-overexpressing transgenic mice exhibited the exacerbation of the indices of nephropathy, and this was prevented by the inhibition of AGE formation. We also created RAGE-deficient mice by homologous recombination. They showed marked amelioration of diabetic nephropathy as compared with wild-type mice. Through an analysis of vascular polysomal poly(A)+ RNA, we identified a novel splice variant coding for a soluble RAGE protein and named it endogenous secretory RAGE (esRAGE). esRAGE was able to protect AGE-induced vascular cell injuries as a decoy receptor and was actually detected in human circulation. We conclude that RAGE plays an active role in the development of diabetic vascular complications, especially nephropathy, and is a promising target for overcoming this disease. The esRAGE, an endogenous decoy receptor, may be related to individual variations in resistance to the development of diabetic vascular complications.

MeSH terms

  • Animals
  • Diabetic Nephropathies / physiopathology*
  • Humans
  • Mice
  • Mice, Transgenic
  • Nitric Oxide Synthase / genetics
  • Nitric Oxide Synthase Type II
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / deficiency
  • Receptors, Immunologic / genetics
  • Receptors, Immunologic / physiology*

Substances

  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic
  • NOS2 protein, human
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse